Eganelisib
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
What will happen during the trial?
The study consists of 2 parts:
- Part 1: Dose Escalation (DE) in both monotherapy and in combination.
- Part 2: Dose Optimization
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 125 patients (estimated)
- Sponsors
- Stelexis BioSciences
- Tags
- PI3K Inhibitor, Randomization, High Risk
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2185
- NCT Identifier
- NCT06533761
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.